Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
murine norovirus vaccine + IgA
- Development stage
- Preclinical
- Lead developer
- Yale University
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular, Subcutaneous, Parenteral
01
Overview
**Murine norovirus vaccine + IgA** refers to the experimental combination or comparative study of a murine norovirus (MNV) vaccine and immunoglobulin A (IgA) therapy. In preclinical research led by Yale University and collaborating institutions, researchers investigated the correlates of protective immunity against norovirus. They demonstrated that while systemic vaccination with the viral capsid protein (VP1) generates a robust systemic IgG response, it fails to protect against enteric norovirus infection. In contrast, mucosal IgA (specifically dimeric IgA delivered prophylactically via mRNA lipid nanoparticles) is necessary and sufficient to confer sterilizing immunity and completely protect against MNV infection in the small intestine. This research highlights the critical role of mucosal IgA in norovirus protection and suggests that IgA-based immunotherapeutics or vaccines designed to elicit mucosal IgA are essential for effective human norovirus prevention.
- Other names
- dimeric anti-norovirus IgA + VP1 vaccinemurine norovirus VP1 vaccine + dimeric IgA
02
Targets
CLEC12ANorovirus VP1
Beyond the preview
Go deeper on murine norovirus vaccine + IgA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on murine norovirus vaccine + IgA.